Prasinezumab

Prasinezumab (PRX 002) is a humanized IgG1 monoclonal antibody directed against aggregated α-synuclein. Prasinezumab has the potential for Parkinson's disease research[1].

Product Specifications

CAS Number

[1960462-19-4]

Product Name Alternative

PRX 002; RG 7935; RO 7046015

UNSPSC

12352203

Target

α-synuclein

Type

Inhibitory Antibodies

Related Pathways

Neuronal Signaling

Applications

Neuroscience-Neurodegeneration

Field of Research

Neurological Disease

Assay Protocol

https://www.medchemexpress.com/prasinezumab.html

Purity

99.90

Solubility

10 mM in DMSO

Smiles

[Prasinezumab]

Molecular Weight

(145.26 kDa)

References & Citations

[1]Gennaro Pagano, et al. A Phase II Study to Evaluate the Safety and Efficacy of Prasinezumab in Early Parkinson's Disease (PASADENA) : Rationale, Design, and Baseline Data. Front Neurol. 2021 Oct 1;12:705407.